Medicure Is Looking Very Good

Medicure (TSXV: MPH) looks very good, rising by 5.26% yesterday to $4 per share. The chart is set up perfectly. You don’t need to be a biotech expert to fully understand why this is the biggest opportunity outside of the natural resource sector and the best way to diversify. PNPO deficiency means the body cannot convert vitamin B6 into its active form, pyridoxal 5′-phosphate.

MPH’s MC-1 is literally pharmaceutical-grade pyridoxal 5′-phosphate, which is the biologically active form of vitamin B6. It works to cure PNPO deficiency, and approval odds next year are close to 100%. MPH will receive an FDA Priority Review Voucher after approval that they will sell for US$200 million.

If you read any news of the FDA shelving the “commissioner’s voucher program”, this has absolutely nothing to do with MPH or the voucher they will receive. MPH will receive a Rare Pediatric Disease Priority Review Voucher (PRV).

Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This communication is for informational and educational purposes only.